Sanofi's Riliprubart granted orphan drug designation in Japan, addressing unmet medical needs

Sanofi’s Riliprubart has been granted orphan drug designation in Japan for CIDP, targeting rare diseases with unmet needs. The monoclonal antibody inhibits activated C1s in the classical complement pathway. Long-term data from a phase 2 trial showed sustained efficacy and safety, with two phase 3 studies underway for further evaluation.

Despite existing treatments, 30% of CIDP patients have inadequate responses, creating a significant unmet medical need. Sanofi presented 76-week data from a phase 2 trial, indicating sustained efficacy and safety of Riliprubart in a broad range of patients. Management highlighted ongoing phase 3 studies to assess the treatment’s potential further.

Sanofi’s Riliprubart has been granted orphan drug designation in Japan, targeting rare diseases with high unmet needs. The monoclonal antibody blocks a specific part of the immune system’s response. Long-term data from a phase 2 trial showed sustained efficacy and safety, with phase 3 studies ongoing for further evaluation.

Read more at Yahoo Finance: Sanofi’s (NASDAQ:SNY) Riliprubart Granted Orphan Frug Designation in Japan